One challenge is that the Epstein–Barr virus expresses very different proteins during its lytic and its latent phases.[which?] To address this, vaccine candidates have been designed to include proteins from both phases.
^Sokal, E.M., Hoppenbrouwers, K., Vandermeulen, C., et al. (December 2007). "Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults". J. Infect. Dis.196 (12): 1749–53. doi:10.1086/523813. PMID18190254.
^Crawford, D.H., Macsween, K.F., Higgins, C.D., et al. (August 2006). "A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis". Clin. Infect. Dis.43 (3): 276–82. doi:10.1086/505400. PMID16804839.